In the landscape of modern drug discovery, the traditional animal study has long been considered a "one-way street." A pathologist examines a glass slide, documents the findings, and the physical specimen is relegated to long-term storage, its data potential largely exhausted. However, a seismic shift is underway. Driven by the rapid maturation of digital pathology—an industry that pivoted from niche curiosity to essential infrastructure during the global pandemic—researchers are now unlocking a wealth of information hidden within legacy tissue archives. By leveraging advanced computational modeling and high-resolution imaging, the scientific community is moving toward a future where we extract more insight from existing biological samples, thereby significantly reducing the necessity for future animal studies.
Main Facts: From Static Glass to Dynamic Data
At the heart of this transformation is the conversion of physical histology into digital assets. Aleksandra Zuraw, DVM, PhD, a veterinary pathologist at Charles River Laboratories, encapsulates the paradigm shift: "Before, the pathology endpoint was just a report. Now you have the digitized slide, which is pixels."
These pixels represent more than just a visual record of a tissue sample. When integrated with historical pathology reports and molecular measurements, digital slides can be used to train artificial intelligence models to recognize subtle, often invisible patterns associated with complex biological changes. This transition effectively transforms archived tissue—previously a static endpoint—into a dynamic, reusable source of data. By applying new computational methods to existing digitized slides, researchers can answer novel scientific questions without ever returning to the vivarium.
A Chronology of the Shift toward Non-Animal Methodologies (NAMs)
The transition toward data-centric pathology did not happen in a vacuum; it is the result of a deliberate, multi-year evolution in regulatory and technical standards.
- 2020–2021 (The Pandemic Catalyst): COVID-19 necessitated remote work for pathologists. Digital pathology infrastructure saw an unprecedented surge in adoption, proving that remote, high-fidelity analysis was not only feasible but often superior for data integration.
- 2022 (Legislative Milestone): The U.S. enacted the FDA Modernization Act 2.0, a landmark piece of legislation that formally allowed non-animal methods to support applications for human clinical trials, effectively breaking the decades-old mandate for animal-only data.
- 2024 (Strategic Advancement): Charles River Laboratories launched its "Alternative Methods Advancement Project," signaling a commitment from industry leaders to integrate these technologies into routine preclinical workflows.
- 2025 (Regulatory Refinement): The OECD released critical guidance on sample collection for omics analysis, providing a framework for how preserved tissue can be utilized for advanced molecular investigations, such as gene expression and protein profiling. Simultaneously, the FDA published a comprehensive roadmap aimed at phasing out mandatory animal testing for biologics and, eventually, new chemical entities.
- 2026 (The Current Frontier): Regulatory updates in September 2026 underscored the FDA’s ongoing commitment to replacing animal models with New Approach Methodologies (NAMs). The field is now focused on "virtual staining" and molecular prediction from standard hematoxylin and eosin (H&E) slides.
Supporting Data: Virtual Controls and FFPE Archives
One of the most promising avenues for reducing animal usage is the implementation of "virtual control groups." In standard toxicology, a significant number of animals are utilized solely as controls—the "placebo" group against which the drug’s effects are measured. By creating high-fidelity, matched historical databases, researchers can now substitute a portion of these live control animals with virtual equivalents.
"Control animals are always a big fraction of every study," notes Dr. Zuraw. By utilizing sophisticated statistical matching, laboratories can draw on historical data to provide a robust baseline, provided the study conditions remain comparable.
Furthermore, the industry is re-evaluating the value of Formalin-Fixed, Paraffin-Embedded (FFPE) tissue blocks. These archives represent a goldmine of biological context. When a question arises about a drug’s mechanism of action after an experiment has concluded, researchers previously had little choice but to initiate a new study. Today, molecular analysis of FFPE blocks allows scientists to revisit the original tissue and extract data on protein and gene expression, effectively mining the past to inform the future.
Official Responses and Regulatory Guidance
The regulatory stance has shifted from cautious oversight to active encouragement of innovation. The FDA’s push to make animal studies the "exception rather than the norm" over the next three to five years is driving a massive investment in the necessary digital infrastructure.
The FDA’s 2025 roadmap explicitly prioritizes monoclonal antibodies as the first class of therapeutics to undergo this transition, with plans to expand the scope to all preclinical safety assessments. This institutional support is crucial because, as Dr. Zuraw points out, the burden of proof rests on the early adopters. "You still need enough early adopters to generate precedent," she says. "Those early adopters will embrace the guidance, figure it out and troubleshoot, and then others can build on their work without reinventing the wheel."
Implications: The "Snowball Effect" on Drug Discovery
The implications of this shift are profound, affecting everything from the speed of drug development to the ethical footprint of the pharmaceutical industry.
Molecular Prediction from H&E
Perhaps the most "cutting-edge" development is the ability to predict molecular profiles directly from standard H&E-stained slides. This approach eliminates the need for expensive, time-consuming special stains or secondary molecular tests. By applying AI models to the rich, visual data of a standard digital slide, researchers can gain deep molecular insights at a fraction of the cost and effort.
Virtual Staining
"Virtual staining"—using software to generate the appearance of complex histological stains on unstained tissue—is another area poised for rapid adoption. This technology promises to skip the physical staining process entirely, potentially reducing chemical waste and minimizing the degradation of tissue samples. As these methods move closer to standardized clinical and research use, the "snowball effect" described by Dr. Zuraw seems inevitable. Labs that invest in high-quality digital scanning infrastructure will find themselves with a competitive advantage, as they will have access to a data treasury that their peers lack.
The Human-Centric Future
Ultimately, the integration of digital pathology into the preclinical pipeline represents a fundamental re-imagining of biological research. By maximizing the utility of every tissue sample and every animal used in a study, the industry is not just increasing efficiency—it is fulfilling a moral and scientific imperative to modernize. As the industry transitions toward these data-driven workflows, the "one-way street" of the pathology lab is becoming a circular, sustainable ecosystem where historical knowledge is continuously repurposed to save lives—both human and animal—more effectively than ever before.
The roadmap is clear: the future of drug discovery lies not in the creation of more data, but in the intelligent, computational extraction of meaning from the data we already possess. As we move closer to the goal of making animal testing the exception, the digital slide stands as the primary bridge to that future.
About the Author
